This retrospective, single-center study found that age had no significant effect on survival of 271 patients age 50-75 years undergoing non-myeloablative haploidentical hematopoietic cell transplantation (HCT). Median age of patients was 61 years, and 84% had intermediate- or high-/very high–risk disease. All patients received non-myeloablative T cell-replete haploidentical HCT with high-dose post-transplantation cyclophosphamide. At a median follow-up of 4 years, patients in their 50s, 60s, and 70s had 3-year progression-free survival of 39%, 35%, and 33% (p=0.65); corresponding 3-year overall survival probabilities were 48%, 45%, and 44% (p=0.66). Older patient age was associated with a significantly higher risk of grade II to IV acute GVHD, but not grade III to IV acute GVHD or chronic GVHD, which the authors attributed to older donor age.
Kasamon YL, et al. J Clin Oncol